[HTML] mdpi.com

[HTML][HTML] Durvalumab as consolidation therapy in post-concurrent chemoradiation (CCRT) in unresectable stage III non-small cell lung cancer patients: a multicenter …

CC Wang, LC Chiu, JS Ju, YC Lin, YF Fang, CT Yang… - Vaccines, 2021 - mdpi.com
Background: The experience of using consolidation durvalumab in post-concurrent
chemoradiation (CCRT) unresectable stage III non-small cell lung cancer (NSCLC) is rare in …
被引用次数：23 相关文章
[HTML] nih.gov

[HTML][HTML] Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A …

CC Wang, LC Chiu, JS Ju, YC Lin, YF Fang, CT Yang… - Vaccines, 2021 - ncbi.nlm.nih.gov
Background: The experience of using consolidation durvalumab in post-concurrent
chemoradiation (CCRT) unresectable stage III non-small cell lung cancer (NSCLC) is rare in …
[PDF] semanticscholar.org

[PDF][PDF] Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A …

CC Wang, LC Chiu, JS Ju, YC Lin, YF Fang, CT Yang… - 2021 - pdfs.semanticscholar.org
Background: The experience of using consolidation durvalumab in post-concurrent
chemoradiation (CCRT) unresectable stage III non-small cell lung cancer (NSCLC) is rare in …

Durvalumab as consolidation therapy in post-concurrent chemoradiation (Ccrt) in unresectable stage iii non-small cell lung cancer patients: A multicenter …

CC Wang, LC Chiu, JS Ju, YC Lin, YF Fang… - Vaccines, 2021 - pure.lib.cgu.edu.tw
Background: The experience of using consolidation durvalumab in post-concurrent
chemoradiation (CCRT) unresectable stage III non-small cell lung cancer (NSCLC) is rare in …

Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter …

CC Wang, LC Chiu, JS Ju, YC Lin, YF Fang, CT Yang… - Vaccines, 2021 - cir.nii.ac.jp
抄録< jats: p> Background: The experience of using consolidation durvalumab in post-
concurrent chemoradiation (CCRT) unresectable stage III non-small cell lung cancer …

Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter …

CC Wang, LC Chiu, JS Ju, YC Lin, YF Fang… - Vaccines, 2021 - search.ebscohost.com
Background: The experience of using consolidation durvalumab in post-concurrent
chemoradiation (CCRT) unresectable stage III non-small cell lung cancer (NSCLC) is rare in …

Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter …

W Chin-Chou, C Li-Chung, JS Ju, L Yu-Ching… - Vaccines, 2021 - search.proquest.com
Background: The experience of using consolidation durvalumab in post-concurrent
chemoradiation (CCRT) unresectable stage III non-small cell lung cancer (NSCLC) is rare in …

Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter …

CC Wang, LC Chiu, JS Ju, YC Lin, YF Fang… - …, 2021 - pubmed.ncbi.nlm.nih.gov
Background The experience of using consolidation durvalumab in post-concurrent
chemoradiation (CCRT) unresectable stage III non-small cell lung cancer (NSCLC) is rare in …

Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter …

CC Wang, LC Chiu, JS Ju, YC Lin, YF Fang, CT Yang… - Vaccines, 2021 - europepmc.org
Background: The experience of using consolidation durvalumab in post-concurrent
chemoradiation (CCRT) unresectable stage III non-small cell lung cancer (NSCLC) is rare in …
[PDF] researchgate.net

[PDF][PDF] Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A …

CC Wang, LC Chiu, JS Ju, YC Lin, YF Fang, CT Yang… - 2021 - researchgate.net
Background: The experience of using consolidation durvalumab in post-concurrent
chemoradiation (CCRT) unresectable stage III non-small cell lung cancer (NSCLC) is rare in …